Overall, due to cross reaction of NOTCH1 signaling with BCR, use of BCR inhibitor Ibrutinib in CLL could downregulate NOTCH1 activity [541]. This evidence concerns the gene NOTCH1 and B-cell chronic lymphocytic leukemia.